Healthcare

Their financial positions also differ significantly. ImpediMed remains loss-making while expanding recurring revenue, Nanosonics has an established profitableBusinessand substantial cash resources, while Lumos is building product revenue around FebriDx as it develops its US commercial presence.

Their FY2026 financial profiles differ substantially. Botanix remains in a cash-intensive commercialisation phase, Clinuvel continues to generate sizeable profit and cash, while Mayne Pharma operates from a much larger revenue base but with pressure on underlying earnings.

Their financial positions also differ substantially. Immutep continues to fund clinical development from its cash resources, Mesoblast is beginning to offset operating costs with product sales, while Dimerix is using licensing payments and other funding sources to support its Phase 3 programme.

Their financial positions reflect very different stages of commercialisation. EBR is generating early commercialRevenuebut remains loss-making, Imricor is still effectively pre-commercial, while Saluda has reached a larger revenue base but continues to record substantial losses and cash outflows.

Their financial profiles are equally different. Radiopharm continues to depend on external capital, Telix is generating profit andOperating Cash Flowfrom commercial products, while Clarity remains pre-commercial but holds a sizeable cash position to support clinical development.

Their financial profiles also differ considerably. Regis operates at scale with positiveEarningsand cash resources, Monash IVF remains profitable but experiencedMarginpressure in FY2026, while Microba is still building toward breakeven as it expands testing volumes and commercial products.

Their latest financial results show differentBusinessprofiles. Pro Medicus combines high-margin softwareRevenuewith a debt-free balance sheet, Integral Diagnostics operates at a much larger revenue scale following its expanded imaging network, while Doctor Care Anywhere is progressing toward a more mature cash-generative telehealth model.